FFO (TTM)

FFO/share (TTM)

FFO/share Guidance

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Occupancy

Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has seven properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I, II, and III retail properties and The Alexander apartment tower, and retail properties located in Paramus, NJ & Flushing, NY.

Alexander's Inc

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 IND clearance received from U.S. FDA for novel EGFR-targeted antibody-drug conjugate (ADC), ALX2004, paving way for mid-year clinical program initiation; Company to host webcast focused on ALX2004 research program on May 20 Company will not pursue U.S. registrational path in gastric cancer following receipt of FDA feedback that accelerated approval pathway is not feasible based on ASPEN-06 due to standard-of-care evolving to ENHERTU® Data milestones expected across Company's three clinical programs in 2026 Cash runway has been extended into Q4 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) --  ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

PARAMUS, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended March 31, 2025 today and reported:

Alexander's Announces First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

PARAMUS, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 30, 2025 to stockholders of record on May 12, 2025.

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising anti-tumor activity

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

SOUTH SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company's investigational CD47-blocker evorpacept, when added to Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) with or without chemotherapy, did not meet the primary endpoints in the ASPEN-03 and ASPEN-04 trials of improved objective response rates (ORR) as compared to historical controls of pembrolizumab alone and pembrolizumab with chemotherapy, respectively, as a first-line treatment in patients with advanced head and neck squamous cell carcinoma (HNSCC). The combination of evorpacept and pembrolizumab with or without chemotherapy in ASPEN-03 and ASPEN-04 demonstrated a manageable safety profile and was consistent with what has been previously reported for pembrolizumab and chemotherapy in this setting. Although the company will no longer pursue evorpacept in combination with pembrolizumab in HNSCC, multiple clinical trials of evorpacept in combination with anti-cancer antibodies will continue based on established proof-of-concept.

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

PARAMUS, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10Q for the quarter ended March 31, 2025 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May 5, 2025, before the New York Stock Exchange opens.

Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

SOUTH SAN FRANCISCO, CALIF., MAY 30, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE JEFFERIES 2025 GLOBAL HEALTHCARE CONFERENCE. DETAILS ARE AS FOLLOWS:

ALX ONCOLOGY TO PRESENT AT THE JEFFERIES 2025 GLOBAL HEALTHCARE CONFERENCE

- A POTENTIAL BEST- AND FIRST-IN-CLASS ANTIBODY-DRUG CONJUGATE (ADC) FOR THE TREATMENT OF EGFR-EXPRESSING SOLID TUMORS, ALX2004 IS UNIQUELY DESIGNED WITH EVERY COMPONENT OPTIMIZED TO MAXIMIZE THE THERAPEUTIC WINDOW BY REDUCING TOXICITY

ALX ONCOLOGY HIGHLIGHTS DIFFERENTIATED DESIGN, PRECLINICAL DATA AND DEVELOPMENT PLANS FOR EGFR-TARGETED ADC, ALX2004, IN R&D WEBCAST EVENT

SOUTH SAN FRANCISCO, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., ("ALX ONCOLOGY" OR THE "COMPANY") (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT IT WILL HOST A WEBCAST EVENT ON MAY 20, 2025, TO PROVIDE AN UPDATE ON ALX2004, THE COMPANY'S POTENTIALLY BEST- AND FIRST-IN-CLASS INVESTIGATIONAL ANTIBODY-DRUG CONJUGATE (ADC). THE WEBCAST WILL HIGHLIGHT THE NOVEL MECHANISM OF ACTION, PRECLINICAL DATA AND CLINICAL DEVELOPMENT STRATEGY FOR ALX2004 FOLLOWING CLEARANCE OF THE INVESTIGATIONAL NEW DRUG APPLICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION EARLIER THIS YEAR.

ALX ONCOLOGY TO HOST R&D WEBCAST EVENT HIGHLIGHTING ITS NOVEL EGFR TARGETING ANTIBODY-DRUG CONJUGATE, ALX2004, ON MAY 20, 2025

FOLLOWING ANNOUNCEMENT OF PRIORITIZED DEVELOPMENT STRATEGY FOR EVORPACEPT IN COMBINATION WITH ANTI-CANCER ANTIBODIES AT R&D DAY IN MARCH, COMPANY IS ON TRACK TO INITIATE PHASE 2 ASPEN-BREAST AND PHASE 1 ASPEN-CRC STUDIES IN MID-2025 IND CLEARANCE RECEIVED FROM U.S. FDA FOR NOVEL EGFR-TARGETED ANTIBODY-DRUG CONJUGATE (ADC), ALX2004, PAVING WAY FOR MID-YEAR CLINICAL PROGRAM INITIATION; COMPANY TO HOST WEBCAST FOCUSED ON ALX2004 RESEARCH PROGRAM ON MAY 20 COMPANY WILL NOT PURSUE U.S. REGISTRATIONAL PATH IN GASTRIC CANCER FOLLOWING RECEIPT OF FDA FEEDBACK THAT ACCELERATED APPROVAL PATHWAY IS NOT FEASIBLE BASED ON ASPEN-06 DUE TO STANDARD-OF-CARE EVOLVING TO ENHERTU DATA MILESTONES EXPECTED ACROSS COMPANY'S THREE CLINICAL PROGRAMS IN 2026 CASH RUNWAY HAS BEEN EXTENDED INTO Q4 2026 SOUTH SAN FRANCISCO, CALIF., MAY 08, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE.

ALX ONCOLOGY REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS ANDPROVIDES CORPORATE UPDATE

PARAMUS, N.J., MAY 05, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NEW YORK STOCK EXCHANGE: ALX) FILED ITS FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2025 TODAY AND REPORTED:

ALEXANDER'S ANNOUNCES FIRST QUARTER FINANCIAL RESULTS

SOUTH SAN FRANCISCO, CALIF., MAY 02, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED PLANS TO REPORT ITS FIRST QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, MAY 8TH, 2025, BEFORE MARKET OPEN.

ALX ONCOLOGY TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 8, 2025

PARAMUS, N.J., APRIL 30, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A REGULAR QUARTERLY DIVIDEND OF $4.50 PER SHARE PAYABLE ON MAY 30, 2025 TO STOCKHOLDERS OF RECORD ON MAY 12, 2025.

ALEXANDER'S DECLARES QUARTERLY $4.50 DIVIDEND ON COMMON SHARES

- DATA TO BE PRESENTED AT AACR 2025 ANNUAL MEETING SUGGEST THE COMBINATION OF ALX ONCOLOGY'S INVESTIGATIONAL CD47-BLOCKER, EVORPACEPT, PLUS RITUXIMAB AND LENALIDOMIDE (R 2 ) WAS WELL-TOLERATED AND DEMONSTRATED PROMISING ANTI-TUMOR ACTIVITY

ALX ONCOLOGY ANNOUNCES ENCOURAGING FINAL RESULTS FROM PHASE 1 TRIAL EVALUATING EVORPACEPT IN COMBINATION WITH STANDARD-OF-CARE TREATMENT IN PATIENTS WITHB-CELL NON-HODGKIN LYMPHOMA

SOUTH SAN FRANCISCO, APRIL 25, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED TOPLINE DATA FROM ITS PHASE 2 ASPEN-03 AND ASPEN-04 CLINICAL TRIALS. THE COMPANY'S INVESTIGATIONAL CD47-BLOCKER EVORPACEPT, WHEN ADDED TO MERCK'S (KNOWN AS MSD OUTSIDE OF THE US AND CANADA) ANTI-PD-1 THERAPY, KEYTRUDA (PEMBROLIZUMAB) WITH OR WITHOUT CHEMOTHERAPY, DID NOT MEET THE PRIMARY ENDPOINTS IN THE ASPEN-03 AND ASPEN-04 TRIALS OF IMPROVED OBJECTIVE RESPONSE RATES (ORR) AS COMPARED TO HISTORICAL CONTROLS OF PEMBROLIZUMAB ALONE AND PEMBROLIZUMAB WITH CHEMOTHERAPY, RESPECTIVELY, AS A FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC). THE COMBINATION OF EVORPACEPT AND PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY IN ASPEN-03 AND ASPEN-04 DEMONSTRATED A MANAGEABLE SAFETY PROFILE AND WAS CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY REPORTED FOR PEMBROLIZUMAB AND CHEMOTHERAPY IN THIS SETTING. ALTHOUGH THE COMPANY WILL NO LONGER PURSUE EVORPACEPT IN COMBINATION WITH PEMBROLIZUMAB IN HNSCC, MULTIPLE CLINICAL TRIALS OF EVORPACEPT IN COMBINATION WITH ANTI-CANCER ANTIBODIES WILL CONTINUE BASED ON ESTABLISHED PROOF-OF-CONCEPT.

ALX ONCOLOGY REPORTS ASPEN-03 AND ASPEN-04 PHASE 2 TRIALS EVALUATING EVORPACEPT WITH A CHECKPOINT INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCERS DID NOT MEET PRIMARY ENDPOINTS

PARAMUS, N.J., APRIL 24, 2025 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT WILL FILE ITS QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH31, 2025 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND ISSUE ITS FIRST QUARTER EARNINGS RELEASE ON MONDAY, MAY5, 2025, BEFORE THE NEWYORK STOCK EXCHANGE OPENS.

Alexander's Inc

ALX

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

ALX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

ALX